GRCE
Neutral signalScored 2026-10-04 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
Research, not advice.
À propos
Grace Therapeutics, Inc.
- Nom
- Grace Therapeutics, Inc.
- Secteur
- Healthcare
- Industrie
- Biotechnology
- Bourse
- NASDAQ
- Capitalisation
- $31.4M
- Employés
- 5
- PDG
- Prashant Kohli
- Site web
- https://www.gracetx.com
- Marché
- ABVCATNMCALCLTRNLVTXOKUR
Grace Therapeutics, Inc. specializes in the creation and commercialization of pharmaceutical products, primarily targeting uncommon and neglected diseases, with operations centered in Canada. The company's most advanced experimental treatment is GTX-104, an intravenous infusion designed to address subarachnoid hemorrhage. Its development pipeline further includes GTX-102, an oral mucosal betamethasone spray intended for the management of ataxia-telangiectasia, and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia. Established in 2002, the enterprise previously operated under the name Acasti Pharma Inc., before officially adopting Grace Therapeutics, Inc. in October 2024. The company's main offices are located in Princeton, New Jersey.
Price (1 year)
Live chart from TradingView — independent market data, as price context around the filings, not the Quorum score. EMA 50/200 and Bollinger load by default. When the exchange is known it is sent as EXCHANGE:SYMBOL; otherwise TradingView resolves the ticker best-effort.
ACHAT TOTAL: 100 000 titres (~214 000,00 $ US)
- Insiders
- Kohli Prashant
- Total bought
-
$214,000
Avg buy (VWAP, 90d window) $2.14 vs last close $2.08 (-2.8%)
- Total sold
-
—
Avg sell (VWAP, 90d window) —
Total sold sums Form 4 code S in this window. Codes F, M, A and G are left out.
- Last activity
- 2026-09-09
- Liquidity
- Illiquid $200,581/day · 20d vol
- Last synced
-
2026-10-10 09:40:27
Sign in to request a sync of this company's price history and timing levels.
Insider holdings as a share of total assets aren't available for this company.
Avg buy and avg sell are volume-weighted prices (sum of shares × price, divided by shares) for Form 4 rows in this 90-day window that report both figures. A comparison with last close is market context for that average, not advice.
Recent Form 4
Filings in the 90-day window for this company. Value is shares × price from the filing. Research, not advice.
| Date | Person | Side | Shares | Price | Value | Form 4 |
|---|---|---|---|---|---|---|
| 2026-09-09 | Kohli Prashant | Buy · P | 100,000 | $2.14 | $214,000 | Form 4 |
Congressional trades
STOCK Act disclosures (90-day window)
Amounts are STOCK Act brackets as disclosed. Quorum does not turn a bracket into an exact price or a midpoint.
No STOCK Act disclosures for this company in this window.
Signal
Neutral signalScored 2026-10-04 Drivers: trend, fundamentals. Moteurs : tendance, fondamentaux.
GRCE presents a compelling event-driven setup — a meaningful insider cluster buy backed by favorable FDA Type A meeting minutes and a $10M placement extending runway to 2028 — but the near-zero fundamental score…
The first sentence of the analysis written for GRCE on 2026-10-04 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Factor checklist — research, not advice
A check leans with a bullish reading. A cross leans against it. A dash is unavailable or mixed.
- Insider Supports a bullish reading. Open-market purchases outweigh sales
- Congress Unavailable or mixed. No purchase disclosures in the stored window
- Narrative Unavailable or mixed. Stored narrative reading is in the neutral band
- Timing Pulls against a bullish reading. Close is more than 0.5 ATR under stored support
- Financial indicators Supports a bullish reading. Current ratio 8.10 · operating margin 0.0%
Suggested stop 1.98, nearest stored support minus 0.5 ATR(4.8% under the last close). Reward/risk to the next stored resistance is 0.70. Wait — that reward/risk is under 2. Research, not advice. Not an order.
Market snapshot
Financial ratios
| Metric | Trend | 2026-03-31 | 2025-03-31 | 2024-03-31 | 2023-03-31 | 2022-03-31 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Ebitda Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Net Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Current Ratio | 8.099 | 11.768 | 14.258 | 8.587 | 13.967 | |
| Quick Ratio | 8.099 | 11.768 | 14.258 | 8.587 | 13.967 | |
| Solvency Ratio | -2.823 | -2.529 | -1.504 | -5.123 | -0.603 | |
| Cash Ratio | 7.911 | 11.468 | 13.661 | 8.172 | 9.306 | |
| Price To Earnings Ratio | -9.851 | -2.018 | -1.645 | -0.390 | -1.490 | |
| Price To Earnings Growth Ratio | 0.169 | 0.053 | 0.022 | -0.001 | 0.018 | |
| Forward Price To Earnings Growth Ratio | 0.169 | 0.053 | 0.022 | -0.001 | 0.018 | |
| Price To Earnings Diluted Ratio | -9.851 | -2.018 | -1.645 | -0.390 | -1.490 | |
| Price To Earnings Diluted Growth Ratio | 0.169 | 0.053 | 0.022 | -0.001 | 0.018 | |
| Price To Book Ratio | 1.196 | 0.414 | 0.465 | 0.329 | 0.171 | |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Price To Free Cash Flow Ratio | -8.619 | -1.849 | -2.322 | -1.405 | -1.072 | |
| Price To Operating Cash Flow Ratio | -8.619 | -1.849 | -2.326 | -1.406 | -1.072 | |
| Debt To Assets Ratio | 0.000 | 0.000 | 0.000 | 0.006 | 0.002 | |
| Debt To Equity Ratio | 0.000 | 0.000 | 0.000 | 0.007 | 0.003 | |
| Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.007 | 0.003 | |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.043 | 1.081 | 1.187 | 1.164 | 1.188 | |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Operating Cash Flow Ratio | -4.133 | -7.722 | -7.324 | -4.665 | -5.287 | |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 1.000 | 1.002 | 1.001 | 1.000 | |
| Debt Service Coverage Ratio | 0.000 | 0.000 | 0.000 | -154.748 | -176.512 | |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | -212.173 | -165.712 | |
| Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | 0.000 | -32.810 | -58.420 | |
| Capital Expenditure Coverage Ratio | 0.000 | 0.000 | -560.591 | -936.059 | 0.000 | |
| Dividend Paid And Capex Coverage Ratio | 0.000 | 0.000 | -560.591 | -936.059 | 0.000 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -5.372 | -0.229 | -0.369 | 0.204 | 0.603 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 0.0% | 0.0% | 0.0% |
| Ebit Margin | 0.0% | 0.0% | 0.0% |
| Ebitda Margin | 0.0% | 0.0% | 0.0% |
| Operating Profit Margin | 0.0% | 0.0% | 0.0% |
| Pretax Profit Margin | 0.0% | 0.0% | 0.0% |
| Continuous Operations Profit Margin | 0.0% | 0.0% | 0.0% |
| Net Profit Margin | 0.0% | 0.0% | 0.0% |
| Bottom Line Profit Margin | 0.0% | 0.0% | 0.0% |
| Current Ratio | 8.099 | ▼-3.669 | ▼-3.237 |
| Quick Ratio | 8.099 | ▼-3.669 | ▼-3.237 |
| Solvency Ratio | -2.823 | ▼-0.294 | ▼-0.306 |
| Cash Ratio | 7.911 | ▼-3.557 | ▼-2.193 |
| Price To Earnings Ratio | -9.851 | ▼-7.833 | ▼-6.772 |
| Price To Earnings Growth Ratio | 0.169 | ▲0.116 | ▲0.117 |
| Forward Price To Earnings Growth Ratio | 0.169 | ▲0.116 | ▲0.117 |
| Price To Earnings Diluted Ratio | -9.851 | ▼-7.833 | ▼-6.772 |
| Price To Earnings Diluted Growth Ratio | 0.169 | ▲0.116 | ▲0.117 |
| Price To Book Ratio | 1.196 | ▲0.783 | ▲0.681 |
| Price To Sales Ratio | 0.000 | 0.000 | 0.000 |
| Price To Free Cash Flow Ratio | -8.619 | ▼-6.770 | ▼-5.566 |
| Price To Operating Cash Flow Ratio | -8.619 | ▼-6.770 | ▼-5.565 |
| Debt To Assets Ratio | 0.000 | 0.000 | ▼-0.002 |
| Debt To Equity Ratio | 0.000 | 0.000 | ▼-0.002 |
| Debt To Capital Ratio | 0.000 | 0.000 | ▼-0.002 |
| Long Term Debt To Capital Ratio | 0.000 | 0.000 | 0.000 |
| Financial Leverage Ratio | 1.043 | ▼-0.038 | ▼-0.089 |
| Working Capital Turnover Ratio | 0.000 | 0.000 | 0.000 |
| Operating Cash Flow Ratio | -4.133 | ▲3.590 | ▲1.693 |
| Operating Cash Flow Sales Ratio | 0.000 | 0.000 | 0.000 |
| Free Cash Flow Operating Cash Flow Ratio | 1.000 | 0.000 | ▼-0.001 |
| Debt Service Coverage Ratio | 0.000 | 0.000 | ▲66.252 |
| Interest Coverage Ratio | 0.000 | 0.000 | 0.000 |
| Short Term Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲75.577 |
| Operating Cash Flow Coverage Ratio | 0.000 | 0.000 | ▲18.246 |
| Capital Expenditure Coverage Ratio | 0.000 | 0.000 | ▲299.330 |
| Dividend Paid And Capex Coverage Ratio | 0.000 | 0.000 | ▲299.330 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -5.372 | ▼-5.143 | ▼-4.340 |
Key metrics
| Metric | Trend | 2026 | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|---|
| Market cap | $76.4M | $27.6M | $28.7M | $22.4M | $18.5M | |
| Enterprise value | $59.5M | $5.4M | $5.7M | -$5.0M | -$11.6M | |
| EV / Sales | 0.00x | 0.00x | 0.00x | 0.00x | 0.00x | |
| EV / Op. cash flow | -6.71x | -0.36x | -0.46x | 0.32x | 0.67x | |
| EV / Free cash flow | -6.71x | -0.36x | -0.46x | 0.31x | 0.67x | |
| EV / EBITDA | -5.37x | -0.23x | -0.37x | 0.20x | 0.60x | |
| Net debt / EBITDA | 1.53x | 0.93x | 1.50x | 1.12x | 1.57x | |
| Current ratio | 8.10x | 11.77x | 14.26x | 8.59x | 13.97x | |
| Income quality | 1.14x | 1.56x | 0.96x | 0.38x | 1.75x | |
| Graham net-net | $1 | $1 | $1 | $2 | $4 | |
| Tax burden | 82.1% | 74.9% | 87.5% | 81.6% | 93.8% | |
| Interest burden | 85.7% | 76.5% | 129.2% | 284.8% | 68.2% | |
| Working capital | $15.2M | $20.8M | $22.3M | $25.9M | $42.3M | |
| Invested capital | $64.5M | $70.1M | $71.6M | $75.7M | $125.4M | |
| Return on assets | -11.7% | -18.9% | -23.8% | -72.5% | -9.5% | |
| Operating ROA | -16.0% | -32.7% | -22.9% | -67.9% | -18.8% | |
| Return on tangible assets | -44.8% | -60.0% | -72.6% | -192.2% | -26.8% | |
| Return on equity | -12.2% | -20.5% | -28.2% | -84.4% | -11.3% | |
| Return on invested capital | -14.1% | -25.4% | -21.3% | -76.0% | -14.6% | |
| Return on capital employed | -17.2% | -33.9% | -24.4% | -93.2% | -15.5% | |
| Earnings yield | -10.2% | -49.4% | -60.8% | -256.4% | -66.4% | |
| Free cash flow yield | -11.6% | -54.1% | -43.1% | -71.2% | -93.2% | |
| Capex / Op. cash flow | 0.0% | 0.0% | -0.2% | -0.1% | 0.0% | |
| Capex / Depreciation | 0.0% | 0.0% | 200.0% | 13.7% | 0.0% | |
| Capex / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| SG&A / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| R&D / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Stock comp / Sales | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Intangibles / Total assets | 73.9% | 68.4% | 67.2% | 62.3% | 64.4% | |
| Days sales outstanding | 0d | 0d | 0d | 0d | 0d | |
| Days payables outstanding | 0d | 0d | 0d | 0d | 0d | |
| Operating cycle | 0d | 0d | 0d | 0d | 0d | |
| Cash conversion cycle | 0d | 0d | 0d | 0d | 0d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Change over 5 years
Employee count
Peer market caps
Recent news
- 2026-09-03 Grace Therapeutics to Participate in the H.C. Wainright 28th Annual Global Investment Conference PRINCETON, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced that Chief Executive Officer Prashant Kohli will participate and present in the H.C.
- 2026-08-13 Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update PRINCETON, N.J., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the financial results and business highlights for the three months ended June 30, 2026.
- 2026-08-04 Grace Therapeutics Announces $10 Million Private Placement Expected gross proceeds anticipated to extend the Company''s cash runway to the end of calendar 2028 Expected gross proceeds anticipated to extend the Company''s cash runway to the end of calendar 2028
- 2026-07-28 Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration FDA Did Not Identify Any Clinical Safety or Efficacy Deficiencies and Did Not Request Additional Clinical Data Company Advancing a Dual-Source Manufacturing Strategy, Adding a U.S.-Based Site, Toward NDA Resubmission PRINCETON, N.J., July 28, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced receipt of the U.S. Food and Drug Administration (FDA) meeting minutes from a Type A Meeting held with the FDA to discuss the Complete Response Letter (CRL) issued on April 23, 2026.
- 2026-07-23 Grace Therapeutics (NASDAQ:GRCE) Trading Down 2.5% – Here’s What Happened Grace Therapeutics, Inc. (NASDAQ: GRCE - Get Free Report)''s share price fell 2.5% on Wednesday. The stock traded as low as $2.36 and last traded at $2.37. 103,999 shares traded hands during mid-day trading, a decline of 53% from the average daily volume of 223,157 shares. The stock had previously closed at $2.43. Analysts Set
- 2026-06-18 Grace Therapeutics Announces 2026 Fiscal Year-End Financial Results, Provides Business Update Type A Meeting Scheduled with FDA to Potentially Clarify Path to GTx-104 NDA Resubmission Phase 3 STRIVE-ON Safety Trial Data Presented at Multiple Medical Conferences Company Continues Disciplined Pre-Commercial Planning in Anticipation of Potential FDA Approval of NDA Resubmission for GTx-104 for the Treatment of Patients with aSAH PRINCETON, N.J., June 18, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced the financial results and business highlights for the fiscal year ended March 31, 2026.